Dück K D, Oltmanns G, Knappe J, Holtz H, Richard F
Abteilung für Kardiologie, Medizinischen Akademie Erfurt.
Z Gesamte Inn Med. 1988 Dec 1;43(23):685-8.
In altogether 54 patients with high blood pressure of the clinical degrees of severity I-IV the blood pressure-reducing effectiveness of the calcium antagonist nifedipine was investigated both in the framework of an oral long-term therapy and especially in problematic situations of high blood pressure. According to the results of own treatment nifedipine is particularly suited for the antihypertensive combination therapy with beta-receptor blockers. Monotherapeutically favourable possibilities of application exist in hypokinetic types of the regulation of circulation as well as in elderly hypertensives. Therapy-resistant as well as crisis-like developments of high blood pressure react with excessive, well tolerable and persisting reductions of blood pressure. Above all with regard to this still little considered indication in the meantime nifedipine represents an unavoidable enrichment in the therapeutic basis spectre of the hypertonus.
在总共54例临床严重程度为I-IV级的高血压患者中,研究了钙拮抗剂硝苯地平在口服长期治疗框架内,特别是在高血压问题情况下的降压效果。根据自身治疗结果,硝苯地平特别适用于与β受体阻滞剂联合进行抗高血压治疗。在循环调节的低动力型以及老年高血压患者中,存在单药治疗的有利应用可能性。对治疗耐药以及高血压的危象样进展,硝苯地平可使血压过度、耐受性良好且持续降低。尤其是鉴于目前这个仍较少被考虑的适应症,硝苯地平无疑是高血压治疗基础药物谱中的一个有益补充。